

Chemical Science

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: C. Sun, Y. Shen, H. Li, Z. Wang, Y. Li, M. Huang, Z. Zou, J. Liu, A. Liu, Y. Pan, W. Zhang and Y. Wang, *Chem. Sci.*, 2025, DOI: 10.1039/D5SC02691A.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.

ARTICLE

A practical photocatalytic strategy for radical (deuterio)difluoromethylation from imidazolium reagents

Chao Sun, Yinpu Shen, Heyin Li, Zhen Wang, Yifan Li, Mengjun Huang, Zhenlei Zou, Jing Liu, Ao Liu, Yi Pan, Weigang Zhang,* Yi Wang*

Received 00th January 20xx,
Accepted 00th January 20xx

DOI: 10.1039/x0xx00000x

The difluoromethyl group (CF₂H) has garnered significant interest in medicinal chemistry owing to its unique biochemical and physicochemical properties. Its deuterated counterpart (CF₂D), building on the established utility of CF₂H, exhibits multifaceted potential for advancing biomedical research and therapeutic development. While the incorporation of difluoromethyl group (CF₂H) into drug molecules has matured, efficient installation of their deuterated counterparts (CF₂D) remains a formidable challenge in medicinal chemistry. This study reports a novel (deuterio)difluoromethyl imidazolate reagent **IMDN-SO₂CF₂X** (X=D, H), which successfully constructs various highly selective (deuterio)difluoromethyl compounds in the form of (deuterio)difluoromethyl radicals while maintaining high deuteration rates, achieving >99% isotopic purity in deuterium incorporation. The reagent enables precise CF₂D and CF₂H installation in natural products and synthetic bioactive compounds, showing broad substrate compatibility. This establishes a robust deuteration platform for drug discovery.

Introduction

Deuterium labeling technology, capitalizing on kinetic isotope effects (KIE), enables precise molecular tracing while preserving the structural integrity of chemical configurations, biological functionalities, and thermodynamic stability.^{1–5} This methodology provides an atomic-level toolkit for real-time monitoring of biomedical material interfaces and systematic deciphering of metabolic networks in multiscale biological systems.^{6–8} Deuterium incorporation strategies have emerged as a key tool in medicinal chemistry for modulating the pharmacokinetic profiles (absorption, distribution, metabolism, and excretion; ADME) of drug candidates, particularly by altering C–H bond cleavage kinetics through kinetic isotope effects.^{9,10} In recent years, multiple deuterated drugs (deutetrabenazine/Austedo® for Huntington's disease treatment) have advanced into clinical trials, signifying accelerated industrial translation of deuterium-incorporated drug development¹¹ (Figure 1A).

Recently, the difluoromethyl group (CF₂H) has attracted significant attention owing to its unique biochemical and

physicochemical properties^{12–16} (Figure 1A). The introduction of CF₂H groups can modulate key pharmacokinetic parameters, including membrane permeability, target binding affinity, and metabolic stability.^{17–19} Building upon the well-established applications of the difluoromethyl group (CF₂H),^{20–31} the deuterated counterpart CF₂D group exhibits multifunctionality and developmental potential, holding significant research value and promising applications in biomedical fields. Synthetic strategies for deuteriodifluoromethyl (CF₂D) compounds can be broadly categorized into three classes (Figure 1B): the defunctionalization of α -functionalized difluoromethyl compounds, followed by deuteration, yields deuteriodifluoromethyl (CF₂D) compounds with moderate-to-high deuterium incorporation;^{32–41} Synthesis of deuteriodifluoromethyl (CF₂D) compounds via deuteriodifluoromethylation reagents;^{42–44} deuteriodifluoromethyl compounds can also be prepared by functional group conversion from deuterated precursors.^{45–47} It is noteworthy that the direct construction of target compounds using deuteriodifluoromethyl radical remains challenging, primarily due to the lack of universal synthesis methods.^{48–51}

Conventional methods for generating deuteriodifluoromethyl radical ($\cdot$ CF₂D) via activation of deuteriodifluoromethylation reagents are primarily categorized into two types: the deuterated difluoromethyl 2-pyridyl sulfone reagent developed by Hu's work, etc, which focuses on validating the radical generation mechanism;^{48–50} deuterated Sodium difluoromethylsulfonate (CF₂DSO₂Na) reported by Li's research group. Although this reagent can

State Key Laboratory of Coordination Chemistry, Jiangsu Key Laboratory of Advanced Organic Materials, and Collaborative Innovation Center of Advanced Microstructures, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China. E-mail: yiwang@nju.edu.cn

† Electronic Supplementary Information (ESI) available: See DOI: 10.1039/x0xx00000x



generate $\cdot\text{CF}_2\text{D}$ radicals through metal catalysis and selectively modify the **C2** position of indole compounds,⁵¹ its substrate applicability remains limited (Figure 1C).

Fluorosulfonyl difluoroacetic acid methyl ester ($\text{FSO}_2\text{CF}_2\text{CO}_2\text{Me}$, MFSDA or Chen's reagent) is a versatile precursor widely used in trifluoromethylation, difluorocarbene generation, and difluoroalkylation reactions to access diverse fluorinated products.⁵²⁻⁵⁴ Our group has dedicated extensive

efforts to the exploration of imidazole-salt-derived fluorinating reagents.⁵⁵⁻⁶¹ By leveraging the Heteroaromatic Activation (HetAr Activation) strategy, we have developed diverse reagent systems enabling trifluoromethylation, polyfluoroalkylation, and fluorosulfonylation. Nevertheless, the design of deuterium-labeled difluoromethylation reagents and their application in selective difluoromethylation remains a significant challenge.




Figure 1. Origin of the reaction design.

Therefore, we attempted to combine Chen's reagent with imidazole to construct a benzimidazolium fluorosulfonate reagent. The positive charge of the resulting benzimidazolium fluorosulfonate can be delocalized on both nitrogens. By the

homolytic cleavage of the weak N-S bond ($\text{BDE} \approx 70$ kcal/mol),⁵⁶ this cationic complex undergoes SET process to generate deuteriodifluoromethyl radical or difluoromethyl radical.



Herein, we developed a versatile imidazole salt reagent (**IMDN-SO₂CF₂X**, X = D/H; **2a**, **2b**) with high reactivity, practicality, and air stability (Figure 1D). This reagent enables: Radical-mediated stereoselective difluoromethylation and deuteriodifluoromethylation of olefins, difluoromethylation of heteroaromatic hydrocarbons (both deuterated and non-deuterated), functionalization of α,β -unsaturated olefins with CF₂D/CF₂H groups. Additionally, it provides a general platform for synthesizing (deuterio)difluoromethylated architectures (Figure 1E).

Results and discussion

Our initial investigation began with 4-vinylbiphenyl **1a** as the model substrate (Table 1). After extensive screening of reaction conditions, we found that when using 1.5 equiv. of benzimidazolium sulfonate reagent (**IMDN-SO₂CF₂D**, **2a**, $E_{1/2}^{\text{red}} = 0.732$ V vs SCE), 2 mol% of 4DPAIPN, and 1.0 equiv. of 4-vinylbiphenyl in THF (Tetrahydrofuran) (1.0 mL) under irradiation with 60 W blue LEDs (entry 1), the (*E*)-CF₂D-alkene product **4a** could be obtained in 71% GC yield and the conversion of **1a** was 90%, and no (*Z*)-CF₂D-alkene products were observed in this condition. We then conducted control experiments to verify the necessity of light source and photocatalyst in the reaction (entries 2 and 3). The results showed that without either the light source or the photocatalyst, the reaction did not proceed, and the starting material remained largely unconsumed. Subsequently, by screening reaction times, we found that upon extending the reaction time to 18 hours, the starting material was fully consumed, the GC yield was 75% (with an isolated yield of 70%) (entry 4). Building on these findings, we then optimized the photocatalysts and solvents separately. When the photocatalyst was replaced with 4CZIPN, only trace amounts of product were formed (entry 5); When *fac*-Ir(ppy)₃ was used as a photocatalyst, **1a** had a great conversion (>95%) with a GC yield of 41%, (entry 6). For solvent screening: DME (1,2-Dimethoxyethane) provided >95% conversion and 47% GC yield (entry 7); 2-Me-THF (2-Methyltetrahydrofuran) improved

conversion to >95% and 70% GC yield (entry 8). Notably, when the solvent was switched to MeCN (entry 9), the reaction barely occurred, yielding only trace products (as illustrated in SI, Supplementary Table 4-7).

With the optimized reaction conditions in hand, we next examined the generality of this transformation with different alkenes and heteroarenes. Using 2 mol% of 4DPAIPN, and **IMDN-SO₂CF₂X** salt **2** (1.5 equiv.) at ambient temperature, a range of alkenes underwent radical (deuterio)difluoromethylation with high efficiency. As shown in Scheme 1, this strategy has demonstrated broad applicability, not only effectively acting on simple mono-substituted alkenes (**4a-4e**), but also showing excellent performance for complex alkenes containing ester and amino groups (**4k-4r**). The experimental results indicate that these substrates can all complete the reaction with good yields, high selectivity, and high deuterium incorporation rates. Furthermore, this method also exhibits excellent applicability to di- and tri-substituted alkenes (**4f-4j**), achieving high levels of yield and deuterium incorporation. Notably, isomerization of the alkene was observed in product **4g**. Moreover, natural products derivatized olefin involving menthol, cholesterol and bexarotene can also be tolerated under the mild photocatalytic conditions and obtained the corresponding alkenyl (deuterio)difluoromethylation products in moderate yields (**4q-4s**). Notably, for product **4s**, the *E/Z* ratio is 1:1, which may arise from the symmetric steric environment imposed by the two phenyl rings.

Heteroaryl-CF₂H, as a key structural motif in drug development, has attracted significant interest. By variation of the reaction conditions, we extended this radical (deuterio)difluoromethylation protocol to heteroarenes. This method developed herein enables efficient deuterated and non-deuterated difluoromethylation of diverse aromatic compounds (Scheme 1). Heteroarene derivatives such as quinoxalinone derivatives, quinolinone derivatives, and benzofuran derivatives were also compatible and generated the desired products (**5a-5d**) in moderate to good yields (62–85%). Moreover, this strategy enables efficient functionalization of heteroaromatic drug molecules (Coumarin and Angelicin) via direct radical (deuterio)difluoromethylation, achieving moderate yields under mild conditions (**5e, 5f**).

By modifying the reaction conditions, including the light source, catalyst, and other parameters, we extended this radical (deuterio)difluoromethylation protocol to acrylates. As shown in Scheme 2, electron-deficient acrylates were compatible with this transformation, affording β -CF₂D/CF₂H carbonyls and related compounds (**7a-7g**) in moderate yields. Notably, the method consistently provides 99% deuterium incorporation across diverse heteroaromatic substrates.

In the substrate scope investigation, it was observed that most substrates exhibited comparable yields and selectivity between deuteriodifluoromethylation and difluoromethylation, though the

Table 1 Optimization of the reaction conditions

Entry	variation from the above conditions	Conversion ^[a]	Yield of 4a ^[b]
1	standard condition	90%	71%
2	w/o photocatalyst	< 5%	0
3	In the darkness	< 5%	0
4	18 h instead of 12 h	> 95%	75%(70%) ^[c]
5	4CZIPN instead of 4DPAIPN	< 5%	Trace
6	<i>fac</i> -Ir(ppy) ₃ instead of 4DPAIPN	> 95%	41%
7	DME instead of THF	> 95%	47%
8	2-Me-THF instead of THF	> 95%	70%
9	MeCN instead of THF	<5%	Trace


^a Yield determined by gas chromatography (GC) using dodecane as an internal standard; ^b GC yield with dodecane as the internal standard. ^c Isolated yield.



deuterated variant required longer reaction times. However, certain substrates showed notable differences in yield and selectivity, likely due to their inherent structural properties.


After the applicability of **IMDN-SO₂CF₂X** (X = D/H; **2a**, **2b**) for (deuterio)difluoromethylation in olefinic and heteroaromatic substrates was demonstrated, its reactivity was systematically evaluated under photocatalytic conditions. As shown in Scheme 3, the three-component reaction of 4-phenylstyrene, **IMDN-SO₂CF₂X** reagent **2**, and oxygen nucleophile reagents

(methanol, phenol, and acetic acid) obtained good yields of *o*-methoxy compound **8a**, *o*-phenoxy compound **9a**, and *o*-acetate compound **10a**. In addition, the 5-heteroaromatic-substituted alkene **11b** undergoes (deuterio)difluoromethylation, followed by migration of the heteroaromatic group to the distal end, to afford the corresponding ketone product **13**, in high yield. Under photocatalytic conditions, substrates **11c**, **11d**, and **11a** undergo distinct radical-initiated tandem cyclization reactions,



Scheme 1. Substrate scope of the olefins and heteroaromatic. Condition A: alkynes **1** (0.10 mmol), **2a** (1.5 equiv.), 4DPAIPN (2 mol%) in THF (1.0 mL) under Ar and 60 W Blue LEDs for 18 h. Condition B: alkynes **1** (0.10 mmol), **2b** (1.5 equiv.), 4DPAIPN (2 mol%) in THF (1.0 mL) under Ar and 60 W Blue LEDs for 12 h. Condition C: alkynes **3** (0.10 mmol), **2a** (1.5 equiv.), 4DPAIPN (2 mol%) in IA (Isopropyl acetate) (1.0 mL) under Ar and 60 W Blue LEDs for 18 h. Condition D: alkynes **3** (0.10 mmol), **2b** (1.5 equiv.), 4DPAIPN (2 mol%) in IA (Isopropyl acetate) (1.0 mL) under Ar and 60 W Blue LEDs for 12 h.






Scheme 2. Substrate scope of the α,β -unsaturated olefins Condition E: alkynes **6** (0.10 mmol), **2a** (1.5 equiv.), Cyclohexa-1,4-diene (2.5 equiv.), 4DPAIPN (2 mol%) in 2-Me-THF (1.0 mL) under Ar and 90 W Blue LEDs for 24 h. Condition F: alkynes **6** (0.10 mmol), **2b** (1.5 equiv.), Cyclohexa-1,4-diene (2.5 equiv.), 4DPAIPN (2 mol%) in 2-Me-THF (1.0 mL) under Ar and 90 W Blue LEDs for 24 h.

affording isoquinoline-1,3-dione **14**; 1,3-benzoxazine **15**; and lactone **12** in 68–91% yields, respectively. These reactions and radical-polar crossover transformations highlight the significant potential of the **IMDN-SO₂CF₂X** (X = D/H; **2a**, **2b**) reagent for synthetic applications in the radical functionalization of olefins.

It is gratifying to note that **IMDN-SO₂CF₂X** reagent **2** demonstrates good to excellent yields and selectivity for (deuterio)difluoromethylation across diverse reaction types. It also shows favorable performance in the modification of bioactive molecule derivatives through (deuterio)difluoromethylation. Based

on its robust performance in various reactions, this reagent holds significant potential for future applications in the synthesis of pharmaceutical molecules.

To probe the reaction mechanism, we performed a series of mechanism-validation experiments. First, 2.5 equiv. of TEMPO were added to the baseline reaction system (Scheme 4A). This addition significantly suppressed the reaction progress. Concurrently, the TEMPO-CF₂D adduct was identified via GC-MS analysis, indicating the involvement of radical intermediates. The radical clock experiment was carried out using cyclopropyl styrene **11e**. Under the standard conditions with MgCl₂ additive, the ring-opened




Scheme 3. Extension of experiments



product **16a-D** can be obtained in 27% (99% D-incorporation) isolated yield (Scheme 4B). This result indicated the potential involvement of deuteriodifluoromethyl radical ($\cdot\text{CF}_2\text{D}$) in the reaction.

From the above mechanistic experiments, we speculate on the possible mechanism of the reaction (Scheme 4C): First, under the irradiation, the cationic **IMDN-SO₂CF₂X** reagent **2** can be reduced by excited state photocatalyst (PC^*) to generate (deuterio)difluoromethyl radical. Then the addition of (deuterio)difluoromethyl radical to the unsaturated

hydrocarbons (**1**, **3**, **6**) furnishes radical intermediate I-IV. Then the intermediate I-II was oxidized by PC^+ to undergo hydrogen eliminated to get the corresponding product (**4**, **5**) and regenerate PC. The intermediate III followed by hydrogen atom transfer with cyclohexa-1,4-diene **17** to furnish the product **7**. On the other hand, the intermediate IV was oxidized by PC^+ and then attacked by appropriate nucleophiles to provide the 1,2-difunctionalized product (**8**, **9**).



Scheme 4. Study of reaction mechanisms

Experimental

General Procedure for the synthesis of products (4a-4s)-D.

Condition A: Under argon, to a solution of 4DPAIPN (2 mol%), and **IMDN-SO₂CF₂D** reagent **2a** (0.15 mmol, 1.5 equiv.) in dried THF (Tetrahydrofuran) (1.0 mL) was added corresponding alkenes **1** (0.1 mmol) at room temperature. After that, the tube was exposed to a 60 W blue LEDs about 18 h until the reaction was completed as monitored by TLC analysis. The reaction mixture was evaporated in vacuo. The crude products were directly purified by flash chromatography on silica gel to give the desired products.

General Procedure for the synthesis of products (4a-4s)-H.

Condition B: Under argon, to a solution of 4DPAIPN (2 mol%),

and **IMDN-SO₂CF₂H** reagent **2b** (0.15 mmol, 1.5 equiv.) in dried THF (Tetrahydrofuran) (1.0 mL) was added corresponding alkenes **1** (0.1 mmol) at room temperature. After that, the tube was exposed to a 60 W blue LEDs about 12 h until the reaction was completed as monitored by TLC analysis. The reaction mixture was evaporated in vacuo. The crude products were directly purified by flash chromatography on silica gel to give the desired products.

General Procedure for the synthesis of products (5a-5f)-D.

Condition C: Under argon, to a solution of 4DPAIPN (2 mol%), and **IMDN-SO₂CF₂D** reagent **2a** (0.15 mmol, 1.5 equiv.) in dried IA (Isopropyl acetate) (1.0 mL) was added corresponding heterocyclic compounds **3** (0.1 mmol) at room temperature. After that, the tube was exposed to a 60 W blue LEDs about 18 h until the reaction was completed as monitored by TLC analysis. The reaction mixture was evaporated in vacuo. The



crude products were directly purified by flash chromatography on silica gel to give the desired products.

The data that support the findings of this study are available in the ESI[†] or on request from the corresponding author. [DOI: 10.1039/D5SC02691A](https://doi.org/10.1039/D5SC02691A)

General Procedure for the synthesis of product (5a-5f)-H.

Condition D: Under argon, to a solution of 4DPAIPN (2 mol%), and **IMDN-SO₂CF₂H** reagent **2b** (0.15 mmol, 1.5 equiv.) in dried IA (Isopropyl acetate) (1.0 mL) was added corresponding heterocyclic compounds **3** (0.1 mmol) at room temperature. After that, the tube was exposed to a 60 W blue LEDs about 12 h until the reaction was completed as monitored by TLC analysis. The reaction mixture was evaporated in vacuo. The crude products were directly purified by flash chromatography on silica gel to give the desired products.

General Procedure for the synthesis of product (7a-7g)-D.

Condition E: Under argon, to a solution of 4DPAIPN (2 mol%), and **IMDN-SO₂CF₂D** reagent **2a** (0.15 mmol, 1.5 equiv.) and Cyclohexa-1,4-diene (0.25 mmol, 2.5 equiv.) in dried 2-Me-THF (2-Methyltetrahydrofuran) (1.0 mL) was added corresponding alkenes **6** (0.1 mmol) at room temperature. After that, the tube was exposed to a 90 W blue LEDs about 24 h until the reaction was completed as monitored by TLC analysis. The reaction mixture was evaporated in vacuo. The crude products were directly purified by flash chromatography on silica gel to give the desired products.

General Procedure for the synthesis of product (7a-7g)-D.

Condition F: Under argon, to a solution of 4DPAIPN (2 mol%), **IMDN-SO₂CF₂H** reagent **2b** (0.15 mmol, 1.5 equiv.) and Cyclohexa-1,4-diene (0.25 mmol, 2.5 equiv.) in dried 2-Me-THF (2-Methyltetrahydrofuran) (1.0 mL) was added corresponding alkenes **6** (0.1 mmol) at room temperature. After that, the tube was exposed to a 90 W blue LEDs about 24 h until the reaction was completed as monitored by TLC analysis. The reaction mixture was evaporated in vacuo. The crude products were directly purified by flash chromatography on silica gel to give the desired products.

Conclusions

In summary, we have described an air-stable redox-active imidazolium fluorosulfonate reagent **IMDN-SO₂CF₂X** (X = D/H; **2a**, **2b**). A key design feature of this radical deuteriodifluoromethylation/difluoromethylation reagent is the cationic nature, which favors the stepwise formation of deuteriodifluoromethyl/difluoromethyl radical ($\cdot\text{CF}_2\text{D}/\cdot\text{CF}_2\text{H}$) via a SET reduction process under photocatalytic conditions. Radical scavenger experiments and radical clock experiments collectively confirm that the reaction proceeds via a radical mechanism. This reservoir of deuteriodifluoromethyl/difluoromethyl radicals can engage with diverse heteroarenes and olefins, yielding a diverse array of functionalized deuteriodifluoromethylation and difluoromethylation compounds. Further study of this highly reactive and bench-stable solid reagent is underway in our laboratory.

Data availability

Author Contributions

C. S. conducted all experiments and characterized the novel compounds. Y. W., W. Z., C. S. designed the experiments. C. S., W. Z., Y. W. wrote the manuscript. Y. P. was responsible for funding application. Y. S., H. L., Z. W., Y. L., M. H., Z. Z., J. L., and A. L. contributed to the analysis and interpretation of the data.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (Nos.22271147, 22401144 and 22471123).

Notes and references

- W. W. Cleland, *Arch. Biochem. Biophys.*, 2005, **433**, 2-12.
- M. G. Gallego and M. A. Sierra, *Chem. Rev.*, 2011, **111**, 4857-4963.
- J. Atzrodt, V. Derdau, W. J. Kerr and M. Reid, *Angew. Chem. Int. Ed.*, 2018, **57**, 1758-1784.
- M. Shao, J. Keum, J.-H. Chen, Y.-J. He, W. Chen, J. F. Browning, J. Jakowski, B. G. Sumpter, I. N. Ivanov, Y.-Z. Ma, C. M. Rouleau, S. C. Smith, D. B. Geohegan, K.-L. Hong and K. Xiao, *Nat. Commun.*, 2014, **5**, 3180.
- T. D. Nguyen, G. H. Markosian, F.-J. Wang, L. Wojcik, X. G. Li, E. Ehrenfreund and Z. V. Vardeny, *Nat. Mater.*, 2010, **9**, 345-352.
- A. E. Mutlib, *Chem. Res. Toxicol.*, 2008, **21**, 1672-1689.
- R. Maity, O. Dungan, F. A. Perras, J.-W. Li, D.-H. Liu, S.-M. Ren, D. Lehnher, Z. Huang, E. M. Phillips, M. Adeyemo, J. Frimpong, T. Quainoo, Z.-F. Liu and L. Luo, *J. Am. Chem. Soc.*, 2024, **146**, 34141-34151.
- Y.-L. Xu, W.-L. Chen, R.-H. Pu, J. Ding, Q. An, Y. Yang, W.-M. Liu and Z.-Z. Zuo, *Nat. Commun.*, 2024, **15**, 9366.
- J. Helfenbein, C. Lartigue, E. Noirault, E. Azim, J. Legailliar, M. J. Galmier, and J. C. Madelmont, *J. Med. Chem.*, 2002, **45**, 5806-5808.
- T. Pirali, M. Serafini, S. Cargnin and A. A. Genazzani, *J. Med. Chem.*, 2019, **62**, 5276-5297.
- C. Schmidt, *Nat. Biotechnol.*, 2017, **35**, 493-494.
- C.-F. Ni and J.-B. Hu, *Synthesis*, 2014, **46**, 842-863.
- J. Rong, C.-F. Ni and J.-B. Hu, *Asian J. Org. Chem.*, 2017, **6**, 139-152.
- F.-X. Zhang, J.-H. Lin and J.-C. Xiao, *Org. Lett.*, 2022, **24**, 7611-7616.
- J. B. I. Sap, C. F. Meyer, N. J. W. Straathof, N. Iwumene, C. W. am Ende, A. A. Trabanco and V. Gouverneur, *Chem. Soc. Rev.*, 2021, **50**, 8214-8247.
- C.-F. Ni and J.-B. Hu, *Chem. Soc. Rev.*, 2016, **45**, 5441-5454.
- S. Kaneko, T. Yamazaki, and T. Kitazume, *J. Org. Chem.*, 1993, **58**, 2302-2312.



18. R. A. Casero and P. M. Woster, *J. Med. Chem.*, 2009, **52**, 4551-4573.
19. S. Boland, J. Alen, A. Bourin, K. Castermans, N. Boumans, L. Panitti, J. Vanormelingen, D. Laysen and O. Defert, *Bioorg. Med. Chem. Lett.*, 2014, **24**, 4594-4597.
20. T. Liang, C. N. Neumann and T. Ritter, *Angew. Chem. Int. Ed.*, 2013, **52**, 8214-8264.
21. Y.-Q. Ning, X.-Y. Zhang, Y. Gai, Y.-Q. Dong, P. Sivaguru, Y.-Y. Wang, B. R. P. Reddy, G. Zanoni and X.-H. Bi, *Angew. Chem. Int. Ed.*, 2020, **59**, 6473-6481.
22. R. Smits, C. D. Cadicamo, K. Burger and B. Koks, *Chem. Soc. Rev.*, 2008, **37**, 1727-1739.
23. D. E. Yerien, S. B. Vallejo and A. Postigo, *Chem. Eur. J.*, 2017, **23**, 14676-14701.
24. J. Yang, S. Ponra, X.-Z. Li, B. B. C. Peters, L. Massaro, T.-G. Zhou and P. G. Andersson, *Chem. Sci.*, 2022, **13**, 8590-8596.
25. S. M. Banik, J. W. Medley, and E. N. Jacobsen, *Science*, 2016, **353**, 51-54.
26. N. A. Meanwell, *J. Med. Chem.*, 2011, **54**, 2529-2591.
27. Z.-Q. Zhang, C.-Q. Wang, L.-J. Li, J. -L. Piper, Z.-H. Peng, J.-A. Ma, F.-G. Zhang and J. Wu, *Chem. Sci.*, 2023, **14**, 11546-11553.
28. D.-L. Chang, Y. Gu, and Q.-L. Shen, *Chem. Eur. J.* 2015, **21**, 6074-6078.
29. J. Wang, Q.-L. Zhou, L.-J. Zhou, and Z.-X. Zhang. *ACS Catal.* 2024, **14**, 18499-18506.
30. J. Yang, S.-Q. Zhu, F. Wang, F.-L. Qing, and L.-L. Chu. *Angew. Chem. Int. Ed.* 2021, **60**, 4300-4306.
31. S.-N. Luan, T. Castanheiro, and T. Poisson. *Org. Lett.* 2023, **25**, 1678-1682.
32. M. F. Sowaileh, C. Han, R. A. Hazlitt, E. H. Kim, J. P. John and D. A. Colby, *Tetrahedron Lett.*, 2017, **58**, 396-400.
33. S. B. Munoz, C.-F. Ni, Z. Zhang, F. Wang, N. Shao, T. Mathew, G. A. Olah and G. K. S. Prakash, *Eur. J. Org. Chem.*, 2017, **2017**, 2322-2326.
34. H. Dang, A. M. Whittaker and G. Lalic, *Chem. Sci.*, 2016, **7**, 505-509.
35. J. B. I. Sap, N. J. W. Straathof, T. Knauber, C. F. Meyer, M. Médebielle, L. Buglioni, C. Genicot, A. A. Trabanco, T. Noël, C. W. am Ende and V. Gouverneur, *J. Am. Chem. Soc.*, 2020, **142**, 9181-9187.
36. L. Santos, A. Panossian, M. Donnard, J. P. Vors, S. Pazenok, D. Bernier and F. R. Leroux, *Org. Lett.*, 2020, **22**, 8741-8745.
37. X.-L. Zhang, X.-Y. Zhang, Q.-M. Song, P. Sivaguru, Z.-K. Wang, G. Zanoni and X.-H. Bi, *Angew. Chem. Int. Ed.*, 2022, **61**, e202116190.
38. Z.-J. Shen, C. Zhu, X. Zhang, C. Yang, M. Rueping, L. Guo and W.-J. Xia, *Angew. Chem. Int. Ed.*, 2023, **62**, e202217244.
39. L.-W. Huang, W. Liu, L.-L. Zhao, Z.-Y. Zhang and X.-Y. Yan, *J. Org. Chem.*, 2021, **86**, 3981-3988.
40. Q.-Y. Gu, T.-Y. Peng, M.-C. Bo, and Y.-F. Wang, *Chin. J. Org. Chem.*, 2023, **43**, 1832-1842.
41. A. L. Trifonov and A. D. Dilman, *Org. Lett.*, 2021, **23**, 6977-6981.
42. J.-Q. Liang, L.-F. Dong, F. Qian, Y.-J. Kong, M.-X. Wang, X.-Y. Xu, X.-S. Shao and Z. Li, *Chin. Chem. Lett.*, 2022, **33**, 4817-4821.
43. O. R. Gedde, A. Bonde, P. I. Golbækdal and T. Skrydstrup, *Chem. Eur. J.*, 2022, **28**, e202200997.
44. Z.-Y. Deng, J.-H. Lin, J. Cai, and J.-C. Xiao, *Org. Lett.*, 2016, **18**, 3206-3209.
45. W. C. Fu and T. F. Jamison, *Angew. Chem. Int. Ed.*, 2020, **59**, 13885-13890.
46. J.-S. Zhu, H.-L. Zheng, X.-S. Xue, Y.-S. Xiao, Y.-F. Liu and Q.-L. Shen, *Chin. J. Chem.* 2018, **36**, 1069-1074.
47. X. Zeng, J.-M. Yang, W. Deng, X.-T. Feng, H.-Y. Zhao, L.-F. Wei, X.-X. Xue, X.-G. Zhang, *J. Am. Chem. Soc.*, 2024, **146**, 16902-16911.
48. W.-J. Miao, Y.-C. Zhao, C.-F. Ni, B. Gao, W. Zhang and J.-B. Hu, *J. Am. Chem. Soc.*, 2018, **140**, 880-883.
49. B. K. Chi, S. J. Gavin, B. N. Ahern, N. Peperni, S. Monfette and D. J. Weix, *ACS Catal.*, 2024, **14**, 11087-11100.
50. F. Gao, Y.-S. Xiao, Z.-M. Li and Q.-L. Shen, *ACS Catal.*, 2025, **15**, 4644-4653.
51. J.-Q. Liang, G.-G. Wang, L.-F. Dong, X.-W. Pang, J.-W. Qin, X.-Y. Xu, X.-S. Shao and Z. Li, *Org. Lett.*, 2021, **23**, 5545-5548.
52. Q.-Y. Chen and S.-W. Wu, *J. Chem. Soc., Chem. Commun.*, 1989, 705-706.
53. Y.-G. Liu, H. Wu, Y. Guo, J.-C. Xiao, Q.-Y. Chen, and C. Liu, *Angew. Chem. Int. Ed.*, 2017, **56**, 15432-15435.
54. Q.-Q. Xie and J.-B. Hu, *Chin. J. Chem.*, 2020, **38**, 202-212.
55. W.-G. Zhang, Z.-L. Zou, W.-X. Zhao, S. Lu, Z.-G. Wu, M.-J. Huang, X.-C. Wang, Y. Wang, Y. Liang, Y. Zhu, Y.-X. Zheng and Y. Pan, *Nat. Commun.*, 2020, **11**, 2572.
56. W. Zhang, M.-J. Huang, Z.-L. Zou, Z.-G. Wu, S.-Y. Ni, L.-Y. Kong, Y.-X. Zheng, Y. Wang and Y. Pan, *Chem. Sci.*, 2021, **12**, 2509-2514.
57. W.-G. Zhang, H.-Y. Li, X.-J. Li, Z.-L. Zou, M.-J. Huang, J.-Y. Liu, X.-C. Wang, S.-Y. Ni, Y. Pan and Y. Wang, *Nat. Commun.*, 2022, **13**, 3515.
58. M.-J. Huang, J.-W. Ma, Z.-L. Zou, H.-Y. Li, J.-Y. Liu, L.-Y. Kong, Y. Pan, W.-G. Zhang, Y. Liang and Y. Wang, *Chem. Sci.*, 2022, **13**, 11312-11319.
59. H.-Y. Li, X. Zhang, Z. Wang, C. Sun, M.-J. Huang, J. Liu, Y.-F. Li, Z.-L. Zou, Y. Pan, W.-G. Zhang and Y. Wang, *Org. Lett.*, 2024, **26**, 6714-6719.
60. H.-Y. Li, M.-J. Huang, Z.-L. Zou, Z. Wang, Y.-F. Li, C. Sun, W.-Z. Chen, Y. Pan, W.-G. Zhang and Y. Wang, *Chem. Sci.*, 2023, **14**, 13893-13901.
61. H.-Y. Li and Y. Wang, *Synthesis*, 2024, DOI: 10.1055/s-0043-1775417.



The authors confirm that the data supporting the findings of this study are available within the article as its supplementary materials.

